131190-82-4

Basic information

• Product Name: 8-BROMO-5,6-DIFLUORO-2-METHYLQUINOLINE
• Synonyms: 8-BROMO-5,6-DIFLUORO-2-METHYLQUINOLINE
• CAS NO: 131190-82-4
• Molecular Formula: C10H6BrF2N
• Molecular Weight: 258.0621464
• EINECS: 1533716-785-6
• Mol File: 131190-82-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 299.831 °C at 760 mmHg
• Flash Point: 135.133 °C
• Appearance: /
• Density: 1.637 g/cm³
• CAS DataBase Reference: 8-BROMO-5,6-DIFLUORO-2-METHYLQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMO-5,6-DIFLUORO-2-METHYLQUINOLINE(131190-82-4)
• EPA Substance Registry System: 8-BROMO-5,6-DIFLUORO-2-METHYLQUINOLINE(131190-82-4)

Safety Data

• Hazardous Substances Data: 131190-82-4(Hazardous Substances Data)

Usage

General Description

8-Bromo-5,6-difluoro-2-methylquinoline is a chemical compound that belongs to the class of quinoline derivatives. It is a heterocyclic compound containing a quinoline ring system with a bromine atom and two fluorine atoms attached to it. The presence of the methyl group at position 2 adds to its structural complexity. 8-Bromo-5,6-difluoro-2-methylquinoline has potential applications in medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable building block for the synthesis of various bioactive molecules. Additionally, it may also find use as a reagent or intermediate in organic synthesis. However, its specific uses and properties would need to be further studied and characterized through research.

Upstream product

• 123-73-9 trans-Crotonaldehyde 
• 64695-81-4 N-(2-bromo-4,5-difluorophenyl)acetamide 
• 458-11-7 3,4-difluoroacetanilide 
• 3863-11-4 3,4-difluoroaniline 
• 123-73-9 crotonaldehyde 

Downstream Products

• 154357-40-1 9,10-difluoro-2,3-dihydro-3S-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid 
• 80076-46-6 (+/-)-5,6-difluoro-2-methyl-1,2,3,4-tetrahydroquinoline 

Relevant articles and documents

Synthesis process of S-(-)-nadifloxacin chiral intermediate

The invention discloses a synthesis process of an S-(-)-nadifloxacin chiral intermediate, and belongs to the technical field of chemical pharmacy. The synthesis process comprises the following steps: 1, synthesizing an intermediate 1; and 2, synthesizing the S-(-)-chiral intermediate. R binaphthylenediamine is used as a matrix of a chiral ligand, epoxy polysilsesquioxane is grafted on a molecule of N-Boc-L-histidine to form the chiral ligand, on one hand, the ee value is increased by utilizing the chiral characteristic of N-Boc-L-histidine, and on the other hand, the ee value is increased by utilizing the characteristics of nanoscale size and solubility of the epoxy polysilsesquioxane, so that the solubility of the catalyst is increased, and the catalyst can be mixed with the reactant in the nanometer size so as to improve the catalytic performance of the chiral catalyst and improve the reaction yield, such that the chiral ligand and the metal ruthenium are subjected to coordination to form the chiral catalyst so as to provide the good chiral amplification effect;.

DIPHENYLMETHANE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS

The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.

A practical synthesis of (S)-(-)-nadifloxacin: Novel acid-catalyzed racemization of tetrahydroquinaldine derivative

(S)-(-)-Nadifloxacin [(S)-(-)-9-fluro-6,7-dihydro-8-(4-hyroxy-1- piperidyl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, (S)- (-)-OPC-7251], an antibacterial agent, was synthesized from (S)-(-)-5,6- difluoro-2-methyl-1,2,3,4-tetrahydroquinoline (DFTQ), which was prepared by the optical resolution of racemic DFTQ with 2,3-di-O-benzoyl-L-tartaric acid. Racemization of the undesired enantiomer [(R)-(+)-DFTQ] was studied in the presence of various acids and the best result was obtained in the case of methanesulfonic acid. The absolute configuraton of (-)-nadifloxacin was determined as S by X-ray crystallographic analysis.